Key Points
- Insmed CEO William Lewis sold 10,699 shares on March 19 at an average price of $143.52 for proceeds of $1,535,520.48, leaving him with 301,185 shares valued at about $43.23 million (a 3.43% reduction).
- The March 19 sale is part of a larger pattern of disposals since January — Lewis has sold a total of 88,092 shares for roughly $13.8 million across multiple transactions.
- Shares traded down about 5.6% on the report; the company reported a negative EPS (‑$1.54 last quarter) and large negative margins, although analysts maintain an average Buy rating with a $205.57 price target.
Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $143.52, for a total transaction of $1,535,520.48. Following the transaction, the chief executive officer directly owned 301,185 shares of the company's stock, valued at $43,226,071.20. The trade was a 3.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
William Lewis also recently made the following trade(s):
- On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97.
- On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total value of $1,615,228.03.
- On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84.
- On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total value of $470,427.06.
- On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total transaction of $1,700,392.07.
- On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00.
- On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
- On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $412,639.99.
- On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $709,959.68.
Insmed Trading Down 5.6%
Shares of INSM stock opened at $136.00 on Friday. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The firm's 50-day simple moving average is $151.95 and its 200-day simple moving average is $165.96. The firm has a market cap of $29.31 billion, a P/E ratio of -21.22 and a beta of 1.13. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54.
Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same period in the prior year, the firm earned ($1.32) earnings per share. The business's revenue for the quarter was up 152.6% on a year-over-year basis. As a group, equities analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Hsbc Holdings PLC raised its stake in shares of Insmed by 8,052.6% during the 4th quarter. Hsbc Holdings PLC now owns 123,267 shares of the biopharmaceutical company's stock worth $21,493,000 after purchasing an additional 121,755 shares in the last quarter. Rockefeller Capital Management L.P. increased its holdings in Insmed by 88.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 16,775 shares of the biopharmaceutical company's stock worth $2,920,000 after buying an additional 7,863 shares during the last quarter. Corient Private Wealth LLC increased its holdings in Insmed by 34.1% in the fourth quarter. Corient Private Wealth LLC now owns 20,865 shares of the biopharmaceutical company's stock worth $3,631,000 after buying an additional 5,305 shares during the last quarter. Keenan LLC bought a new position in shares of Insmed in the fourth quarter worth about $369,000. Finally, Reflection Asset Management acquired a new position in shares of Insmed during the 4th quarter worth about $30,000.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Cantor Fitzgerald upped their target price on Insmed from $216.00 to $230.00 and gave the company an "overweight" rating in a report on Tuesday, December 16th. Wells Fargo & Company decreased their price target on Insmed from $234.00 to $208.00 and set an "overweight" rating for the company in a research note on Friday, February 20th. Truist Financial set a $205.00 target price on shares of Insmed in a report on Monday, January 12th. Stifel Nicolaus set a $205.00 target price on Insmed in a report on Thursday, February 19th. Finally, Leerink Partners reaffirmed an "outperform" rating on shares of Insmed in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $205.57.
Get Our Latest Report on Insmed
Insmed Company Profile
(
Get Free Report)
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
